Indacaterol Mometasone Inhalation Powder Clinical Trial Approved for Asthma Treatment
March 6, 2026
Source: drugdu
30
On March 5, CSPC Pharmaceutical Group (01093) announced that its indacaterol mometasone inhalation powder has been approved by the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China. This product is primarily used for maintenance treatment of asthma in adults and adolescents aged 12 and above, and has the effects of relaxing smooth muscles and dilating the bronchi.
Indacaterol mometasone inhaler powder is the first once-daily ICS-LABA combination inhaler included in the National Medical Insurance Catalog (2022 Edition), providing asthma patients with a more efficient and convenient treatment option.
https://finance.eastmoney.com/a/202603053663314598.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Anglikang Adenosylcobalamin Capsules Obtain Drug Registration Certificate March 6, 2026
- Two Minoxidil Topical Solution Applications from its Subsidiary Approved March 6, 2026
- Zhejiang Medicine’s ARX305 Initiates Phase II Clinical Trial March 6, 2026
- Harsco Pharmaceutical’s innovative drug HSK50042 tablets receive clinical approval for a new indication March 6, 2026
- Clinical trial application for HLX97 approved by the National Medical Products Administration March 6, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
